{"name":"Mesoblast, Ltd.","slug":"mesoblast-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Standard of Care for GVHD","genericName":"Standard of Care for GVHD","slug":"standard-of-care-for-gvhd","indication":"Graft-versus-host disease","status":"phase_3"},{"name":"Allogeneic Mesenchymal Precursor Cells","genericName":"Allogeneic Mesenchymal Precursor Cells","slug":"allogeneic-mesenchymal-precursor-cells","indication":"Other","status":"phase_2"},{"name":"Prochymal®","genericName":"Prochymal®","slug":"prochymal","indication":"Graft-versus-host disease","status":"phase_3"},{"name":"Provacel","genericName":"Provacel","slug":"provacel","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rexlemestrocel-L + HA Mixture","genericName":"Rexlemestrocel-L + HA Mixture","slug":"rexlemestrocel-l-ha-mixture","indication":"Knee osteoarthritis","status":"phase_3"}]}],"pipeline":[{"name":"Rexlemestrocel-L + HA Mixture","genericName":"Rexlemestrocel-L + HA Mixture","slug":"rexlemestrocel-l-ha-mixture","phase":"phase_3","mechanism":"Rexlemestrocel-L is an allogeneic mesenchymal stem cell therapy combined with hyaluronic acid that promotes tissue repair and reduces inflammation through paracrine signaling and immunomodulation.","indications":["Knee osteoarthritis","Tendon and ligament injuries"],"catalyst":""},{"name":"Standard of Care for GVHD","genericName":"Standard of Care for GVHD","slug":"standard-of-care-for-gvhd","phase":"phase_3","mechanism":"Rexlemestrocel-L is a mesenchymal stem cell therapy that modulates the immune system to treat graft-versus-host disease.","indications":["Graft-versus-host disease"],"catalyst":""},{"name":"Allogeneic Mesenchymal Precursor Cells","genericName":"Allogeneic Mesenchymal Precursor Cells","slug":"allogeneic-mesenchymal-precursor-cells","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Prochymal®","genericName":"Prochymal®","slug":"prochymal","phase":"phase_3","mechanism":"Prochymal is a mesenchymal stem cell therapy that aims to modulate the immune system and promote tissue repair.","indications":["Graft-versus-host disease"],"catalyst":""},{"name":"Provacel","genericName":"Provacel","slug":"provacel","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPUG9VaG91cHN4QlZoQVRUSzZMMTdPTXAwcVlMTzRMRlBpb2ZGMXhTZVpqNHVDeDFEdEFKN1diYnpIT19OWmNDZ1VhZVkyZ01tR0ZyWlE4dmlxWnB6UFM0WTgtLXZEcGQ0WWtRU2JzQkI2S1l2QXBRMjlUS0ItSzJCVl9PbFZTcjJyZy1sY2JnQUQ5bEdVcUZNVXIyZkhNb3d2ajl6MjBPYklTdDItc2I4TVJ3bDZEV0tPLXp4LUFaZVRhNGNtbk5ZSFQ4dUtOT21WN0NxS3BCb0lsVlRvWW1ncTVyZm95YnFyRTV5em9UYkdHdU9JR25FaXlabWNWd0FFRnA3c1VKMDdUVjlxaDBfclIxa3FOZ3RpRW1EQnRpOEV3NHJzZmdyT2R1TEU?oc=5","date":"2026-04-08","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF) and Telix Pharmaceuticals (OtherTLPPF) - The Globe and Mail","headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF) and Telix Pharmaceuticals (OtherTLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBobkpYWGFkcTF3YkdDd0pIYUVnODgwd1RpN3l0Vk5sbmVNekRzMnJUVF96cmlpTzlxc0NUSEhvczNIY3NOTUZSWERsR3g5R0VrZWlkZWJtaGc1bWViZFHSAWNBVV95cUxOMHgwRjRCNGhLd3NvN1dwbTJQNGo2ejl5bmVEZEVWY05xU3RZemJYNXkydHZmSFl5VnNVZE1kRnEwbUpOTDVoOWZTMGF1b3QzN0xGZVJSQnRIY0VwZHJoYXNla1E?oc=5","date":"2025-12-28","type":"pipeline","source":"BioInformant","summary":"Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - BioInformant","headline":"Top Companies Developing Cell Therapy Treatments For Diabetes in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxOamI4SmJMSkJDXzRhb0FVLW5WV2F5VmgwclJ4STFuREoxVExoUjgtdW02NlNrUEJ4R0JieDNlbDd5RFNPNWNPR0YwcEgzVU52a3AzYWlqOFA2ai1XRU9sV1VLRkhoVUdWeEpzYTdleTRSNGI5ZEJlNkFUSkJYRHZLcXRuY29YY25zVm1hYktjYXV1akNMWGc1LUMzZm1LcWlaZEw0d0Y5eWZENmtWdkFkWHdzNFQwQWdOUkdTUW1ZSzVBY25QamJMMUR6eHJlLVVDZWJtSVg5ajVMc2prNUtRYVpYcFRraUtEWHJWaC03SjF1YmxLUTluRGp2NEJYNzFnN2NjV2pzUDE?oc=5","date":"2025-11-26","type":"pipeline","source":"Benzinga","summary":"Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher - Benzinga","headline":"Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-24","type":"trial","source":"Indian Pharma Post","summary":"Mesoblast teams with NIH to launch pivotal trial of life-saving cell therapy in adults with severe aGvHD - Indian Pharma Post","headline":"Mesoblast teams with NIH to launch pivotal trial of life-saving cell therapy in adults with severe aGvHD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPWC10Y0x4c1hKcURIODlQQjV5SWQxNnRKQXNWbHpqaUxadzdqX2tHakFnWU9SRzZKUzJpQkstMmRTN3ppaS13ZjBKdng0S1A0ODhmUUF0SmRpWlpEc2JlVTQyMWszMmRnbDNZSEJDcTg2d1hPc3I2YzE1UWx1WHNzaEVGSEs0SE1idjItVkVEa1hzRjViTlV0TUtxMU52QQ?oc=5","date":"2025-10-22","type":"trial","source":"Meyka","summary":"MESO News Today: Mesoblast’s Regenerative Medicine Trials Drive Market - Meyka","headline":"MESO News Today: Mesoblast’s Regenerative Medicine Trials Drive Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPSkRWd2JhZ244TWVfRTFsNkdDd3JxeExDWm1wNUR0dWYyNFN5V012enIwWkJqWGtoNmxtTGtUQmZYUkxBelpyUjgyR1dTYnZjZUV0ZExBanlaeHBQRUpUdzljOExXVEVBaWRNLXdWTmhfSXZIUXl0Rl9ENGdfeFo4TFhGc3V1akg2SEE?oc=5","date":"2025-10-01","type":"pipeline","source":"Yahoo Finance","summary":"Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs - Yahoo Finance","headline":"Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-01","type":"pipeline","source":"simplywall.st","summary":"Mesoblast Limited (ASX:MSB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st","headline":"Mesoblast Limited (ASX:MSB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-15","type":"deal","source":"simplywall.st","summary":"Insider Stock Buying Reaches US$201.4m On Mesoblast - simplywall.st","headline":"Insider Stock Buying Reaches US$201.4m On Mesoblast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPOFpISUVmRloyZnR4c0dVT25yNVUxS2Frc3U3WHc2d3pxUzEtdmtxRDZWb1gyUUphc1pCSERPMHA3TnkyZlBuRmdHWGNScDJ4OFFDaW1rMHQzWjZFSksxZlQ3YjM0QVl2aHA5ZWJBNjdYdHNrZVZMUWxCSlpZYkJBV1JTZ01lMHZvVXQ2dVYtSnZUZ1hJTWtLSzlMOFlBTEJtTGRoTVRZNFRtTG5QckVzbFVKZG1WTXY1NHRuMXNxc09jV0FfRFV6M1llaDVWSEtWSzVvQzNrSXBMQmZHODBkZ1ZYSEtwVHBhQWkxZVJKVmhVTHNWNm5mYUlMdWNqZHNxaFdaUmhJWG82bUI3elM1NjhmZmJ1S2VX?oc=5","date":"2025-06-16","type":"pipeline","source":"PR Newswire","summary":"Chronic Lower Back Pain Market to Expand Significantly During the Forecast Period (2025-2034) with Game-Changing Therapies | DelveInsight - PR Newswire","headline":"Chronic Lower Back Pain Market to Expand Significantly During the Forecast Period (2025-2034) with Game-Changing Therapi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQUVhkQVlIWm5kdU1mN3pfcVFnbzA1ODhBSEd5Q2phWF95bDluQWZjbEhtRDRSTWFvbU81ZHNCTVlGZkQwM1Y0UXBkUGVNRHZpT053VllKS0YzejEyVEJZbmpTckxjZnNGcDJJUUlhdl9PS3dTeFRXN2VJVlRfODNsYVcyVVVjQktEQXo1UlNVeUw2WnpsajhBYm9aa3A?oc=5","date":"2024-12-19","type":"regulatory","source":"fiercepharma.com","summary":"After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy - fiercepharma.com","headline":"After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZ0owUDV3SUR6VlBKak5NMWwtRVdLN1ZWSjlDZV9iNHZNcmlJMUg2QndmUTVuWXdsemFjekRTQXZHVGcxRnJfUDduR0NzVVpEYms3NUFZUnRmR1F4THEzRXZVYjdxcHdId2dGREtoYTZRWHg4M2hVZ0phV2M5M0xIdW0tSlFtVGh2V1hvYzZRdjhUQVlWWmNhZXJwd3VUME10cEY1NVEwYkVWeExvazZ4NFhTUjEtRDZJZVpWT3Q2LXZHQ2Y0OFU2M2JIMFRJaTBkZVptTzJCNGtYUWdw?oc=5","date":"2023-08-04","type":"regulatory","source":"Reuters","summary":"Mesoblast shares tank after US FDA rejects cell therapy for children - Reuters","headline":"Mesoblast shares tank after US FDA rejects cell therapy for children","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQNnZFbFVJenBodlc1YjRvczVoeVBXNWdQRXRQWFRrWkhnTTFRUVplei1ZN0NCaTlyZ18zaVdPdldrSjA2UU9kb01fMnpUNmtzYm05UlMtZF8wNXpmaGRJQ1BwaDhzLXhBcW5oUjU2Qk5nM191YUhiZUhWOG1EcDF0X09ia1JKUUl2UXc?oc=5","date":"2016-12-23","type":"deal","source":"Drug Delivery Business","summary":"Mesoblast gains on A$29m investment deal with Mallinckrodt - Drug Delivery Business","headline":"Mesoblast gains on A$29m investment deal with Mallinckrodt","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}